Tags

Type your tag names separated by a space and hit enter

Approaches and Challenges in SARS-CoV-2 Vaccine Development.
Cell Host Microbe. 2020 09 09; 28(3):364-370.CH

Abstract

The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.

Links

Publisher Full Text
ncbi.nlm.nih.gov
linkinghub.elsevier.com
PMC Free PDF

Authors+Show Affiliations

Dagotto G
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA.
Yu J
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA.
Barouch DH
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA 02215, USA. Electronic address: dbarouch@bidmc.harvard.edu.

MeSH

AnimalsAntigens, ViralBetacoronavirusCOVID-19COVID-19 VaccinesCoronavirus InfectionsHost Microbial InteractionsHumansImmunity, CellularImmunity, HumoralImmunity, InnateModels, AnimalPandemicsPneumonia, ViralPrimatesSARS-CoV-2Spike Glycoprotein, CoronavirusViral Vaccines

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32798444

Clinical Trial Links

Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations

Citation

Dagotto, Gabriel, et al. "Approaches and Challenges in SARS-CoV-2 Vaccine Development." Cell Host & Microbe, vol. 28, no. 3, 2020, pp. 364-370.
Dagotto G, Yu J, Barouch DH. Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host Microbe. 2020;28(3):364-370.
Dagotto, G., Yu, J., & Barouch, D. H. (2020). Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host & Microbe, 28(3), 364-370. https://doi.org/10.1016/j.chom.2020.08.002
Dagotto G, Yu J, Barouch DH. Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host Microbe. 2020 09 9;28(3):364-370. PubMed PMID: 32798444.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Approaches and Challenges in SARS-CoV-2 Vaccine Development. AU - Dagotto,Gabriel, AU - Yu,Jingyou, AU - Barouch,Dan H, Y1 - 2020/08/10/ PY - 2020/06/09/received PY - 2020/08/04/revised PY - 2020/08/05/accepted PY - 2020/8/18/pubmed PY - 2020/9/22/medline PY - 2020/8/18/entrez KW - COVID-19 KW - SARS-CoV-2 KW - vaccine SP - 364 EP - 370 JF - Cell host & microbe JO - Cell Host Microbe VL - 28 IS - 3 N2 - The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection. SN - 1934-6069 UR - https://www.unboundmedicine.com/medline/citation/32798444/Approaches_and_Challenges_in_SARS_CoV_2_Vaccine_Development_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1931-3128(20)30455-8 DB - PRIME DP - Unbound Medicine ER -